Journal article
Pharmacological blood pressure-lowering for prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual participant data meta-analysis of 46 randomised controlled trials
- Abstract:
-
Background:
Owing to safety concerns, individuals with chronic kidney disease (CKD), particularly those at more advanced stages, have been systematically underrepresented in randomised controlled trials (RCTs) of blood pressure (BP)-lowering treatment, leading to a persistent paucity of evidence for cardiovascular risk management in this high-risk group. We sought to investigate the effect of BP-lowering treatment on the risk of major cardiovascular disease and death acro... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.2MB, Terms of use)
-
(Preview, Supplementary materials, pdf, 3.1MB, Terms of use)
-
- Publisher copy:
- 10.1016/S0140-6736(26)00367-3
Authors
+ British Heart Foundation
More from this funder
- Funder identifier:
- https://ror.org/02wdwnk04
- Grant:
- FS/IPBSRF/22/27060
- PG/18/65/33872
- Publisher:
- Elsevier
- Journal:
- Lancet More from this journal
- Volume:
- 407
- Issue:
- 10539
- Pages:
- 1626-1638
- Publication date:
- 2026-04-25
- Acceptance date:
- 2026-02-18
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Language:
-
English
- Pubs id:
-
2378911
- Local pid:
-
pubs:2378911
- Deposit date:
-
2026-02-19
- ARK identifier:
Terms of use
- Copyright holder:
- Zeng et al.
- Copyright date:
- 2026
- Rights statement:
- ©2026 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record